A
Agnès Veyradier
Researcher at University of Paris
Publications - 208
Citations - 8020
Agnès Veyradier is an academic researcher from University of Paris. The author has contributed to research in topics: Thrombotic thrombocytopenic purpura & ADAMTS13. The author has an hindex of 44, co-authored 193 publications receiving 6692 citations. Previous affiliations of Agnès Veyradier include French Institute of Health and Medical Research & Paris Diderot University.
Papers
More filters
Journal ArticleDOI
Thrombotic thrombocytopenic purpura.
TL;DR: Long-term follow-up of patients with TTP is crucial to identify the occurrence of other autoimmune diseases, to control relapses, and to evaluate psychophysical sequelae.
Journal ArticleDOI
Specific von Willebrand factor–cleaving protease in thrombotic microangiopathies: a study of 111 cases
TL;DR: VWF-cleaving protease deficiency specifically concerns a subgroup of TMA corresponding to the TTP entity, and statistical analysis showed that vWF-protease deficiency was associated with the severity of thrombocytopenia.
Journal ArticleDOI
Screening for von Willebrand Disease With a New Analyzer Using High Shear Stress: A Study of 60 Cases
Edith Fressinaud,Agnès Veyradier,Florence Truchaud,Isabelle Martin,Catherine Boyer-Neumann,Marc Trossaert,Dominique Meyer +6 more
TL;DR: The PFA-100 demonstrates a high sensitivity, clearly superior to that of BT, for the screening of patients with von Willebrand disease, and is well adapted to routine testing, as it has the advantages of simplicity and ease of execution.
Journal ArticleDOI
Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience
Paul Coppo,Michaël Schwarzinger,Marc Buffet,Alain Wynckel,Karine Clabault,Claire Presne,Pascale Poullin,Sandrine Malot,Philippe Vanhille,Elie Azoulay,Lionel Galicier,Virginie Lemiale,Jean-Paul Mira,Christophe Ridel,Eric Rondeau,Jacques Pourrat,Stephane Girault,Dominique Bordessoule,Samir Saheb,Michel Ramakers,Mohamed Hamidou,Jean-Paul Vernant,Bertrand Guidet,M. Wolf,Agnès Veyradier +24 more
TL;DR: The criteria should be useful to identify rapidly newly diagnosed patients with an acquired ADAMTS13 deficiency to better tailor treatment for different pathophysiological groups.
Journal ArticleDOI
Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases
Fadi Fakhouri,Jean Paul Vernant,Agnès Veyradier,Martine Wolf,Gilles Kaplanski,Raynald Binaut,Manfred Rieger,Friedrich Scheiflinger,Pascale Poullin,Benjamin Deroure,Richard Delarue,Philippe Lesavre,Philippe Vanhille,Olivier Hermine,Giuseppe Remuzzi,Jean Pierre Grunfeld +15 more
TL;DR: Rituximab is a promising first-line immunosuppressive treatment in patients with acute refractory and severe relapsing TTP related to anti-ADAMTS13 antibodies.